Damora Reports 95-Fold Preclinical Potency Improvement for DMR-001

The company said DMR-001 showed an average 95-fold improvement in anti-proliferative potency versus a reference antibody across 10 non-Type 1 CALR mutations. The data were accepted for presentation at ASH.